Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Thrilled to be in Boston for Target Cancer Foundation Think Tank on Precision Medicine in Rare Cancers TCF25 !
Delighted to deliver a keynote on ‘Why We Need Molecular Reclassification and Drug Development for Rare Cancers !!!’ This highly interactive meeting brings together clinicians, researchers, industry leaders, advocates and patients to drive innovation.”
Read further.
More posts featuring Vivek Subbiah on OncoDaily.